ArticleCureus2026
Intramedullary Spinal Cord Metastasis From Oligometastatic Melanoma of Unknown Primary Treated With Stereotactic Body Radiotherapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intramedullary spinal cord metastasis (ISCM) is an uncommon and challenging clinical entity with no established consensus regarding its optimal management. A 37-year-old female presented with left-sided facial numbness, right leg paresthesia with decreased temperature sensation, and right lower extremity weakness. Investigations demonstrated two intracranial lesions and an ISCM at T10 to T11. Biopsy of the intracranial lesion confirmed melanoma. The patient was treated with stereotactic body radiotherapy (SBRT) to a dose of 30 Gy in 5 fractions to the ISCM and stereotactic radiosurgery to a dose of 20 Gy in a single fraction to the intracranial metastases. The spinal cord dose received by a 0.035 cc volume was limited to less than or equal to 30 Gy. No spinal cord planning organ-at-risk volume was used. SBRT was followed by combination ipilimumab and nivolumab for four cycles, then maintenance nivolumab thereafter. At 25 months post-SBRT, the treated lesions decreased in size. There were no severe acute or late radiation-related toxicities, and the patient remained fully ambulatory from presentation to last follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.